GlobeNewswire: Tonix Pharmaceuticals Holding Corp. Contains the last 10 of 537 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:38:42ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2854099/0/en/Tonix-Pharmaceuticals-Announces-Pricing-of-4-4-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering2024-03-28T13:32:56Z<![CDATA[CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company for the purchase and sale of 14,666,666 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a registered direct offering at a combined offering price of $0.30 per share and accompanying warrant. The warrants have an exercise price of $0.33 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/03/25/2851559/0/en/Tonix-Pharmaceuticals-Receives-Rare-Pediatric-Disease-Designation-from-the-FDA-for-TNX-2900-for-the-Treatment-of-Prader-Willi-Syndrome.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome2024-03-25T12:00:00Z<![CDATA[TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating]]>https://www.globenewswire.com/news-release/2024/03/21/2850190/0/en/Tonix-Pharmaceuticals-Announces-Poster-Presentation-Describing-Discovery-of-Novel-Next-Generation-Oxytocin-Analogues-at-the-American-Chemistry-Society-ACS-Spring-2024-Meeting.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting2024-03-21T12:00:00Z<![CDATA[Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder]]>https://www.globenewswire.com/news-release/2024/03/20/2849326/0/en/Tonix-Pharmaceuticals-Announces-Selection-of-Two-Contract-Manufacturing-Organizations-for-the-Launch-and-Commercial-Manufacture-of-Tonmya-for-the-Management-of-Fibromyalgia.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia2024-03-20T12:00:00Z<![CDATA[Tonmya™ is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by positive results from two Phase 3 studies]]>https://www.globenewswire.com/news-release/2024/03/19/2848491/0/en/Tonix-Pharmaceuticals-Announces-Transition-to-Fully-Integrated-Biopharmaceutical-Company-Expected-on-April-1-2024.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 20242024-03-19T12:00:00Z<![CDATA[Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix’s wholly-owned commercial subsidiary]]>https://www.globenewswire.com/news-release/2024/03/12/2844458/0/en/Tonix-Pharmaceuticals-Announces-Presentation-at-BIO-Europe-Spring.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring2024-03-12T12:00:00Z<![CDATA[Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia]]>https://www.globenewswire.com/news-release/2024/03/11/2843736/0/en/Tonix-Pharmaceuticals-Reports-Improvement-in-Brain-Fog-in-Fibromyalgia-Patients-Treated-with-Tonmya-in-RESILIENT-an-NDA-Enabling-Phase-3-Clinical-Trial-at-the-6th-International-Con.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia2024-03-11T12:00:00Z<![CDATA[Phase 3 RESILIENT study of Tonmya met its primary endpoint of daily pain reduction (p=0.00005) and achieved statistically significant improvement on all six key pre-specified secondary endpoints with effect sizes on sleep, fatigue, FIQ-R symptoms and FIQ-R function ranging from 0.3 to 0.5]]>https://www.globenewswire.com/news-release/2024/03/07/2842183/0/en/Tonix-Pharmaceuticals-Announces-Publication-in-Psychiatry-Research-Showing-Activity-of-Bedtime-TNX-102-SL-on-PTSD-Symptoms-and-Sleep-Quality-in-Military-Related-PTSD-at-Four-Weeks-.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy2024-03-07T13:00:00Z<![CDATA[Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) and PTSD after civilian motor vehicle collision in upcoming U.S. DoD-Funded Phase 2 investigator-initiated OASIS trial]]>https://www.globenewswire.com/news-release/2024/03/06/2841385/0/en/Tonix-Pharmaceuticals-Selects-EVERSANA-to-Support-Launch-Strategy-and-Commercialization-Planning-of-Tonmya-for-the-Management-of-Fibromyalgia.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia2024-03-06T13:00:00Z<![CDATA[Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials]]>https://www.globenewswire.com/news-release/2024/03/05/2840370/0/en/Tonix-Pharmaceuticals-Announces-Translation-of-Preclinical-Pharmacokinetic-Parameters-of-TNX-1500-Fc-modified-humanized-anti-CD40L-mAb-Supports-Monthly-i-v-Dosing-in-Humans.html?f=22&fvtc=4&fvtv=20531Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans2024-03-05T13:00:00Z<![CDATA[TNX-1500, a third generation anti-CD40L mAb, was Fc-modified to preserve the activity and bioavailability of first generation mAbs while addressing their thrombosis risk]]>